Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)

INTRODUCTION: Prophylactic treatment of severe hemophilia A is burdensome, requiring frequent intravenous injections. Extended half-life (EHL) factor VIII replacement therapies offer longer intervals between infusions while still meeting efficacy and safety outcomes; however, patient perspectives fo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Patient
Hlavní autoři: Wells, Jane R., Gater, Adam, Marshall, Chris, Tritton, Theo, Vashi, Parth, Kessabi, Sophia
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2019
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6884429/
https://ncbi.nlm.nih.gov/pubmed/31313270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40271-019-00374-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky